Syndrome of inappropriate antidiuretic hormone classification

Syndrome of inappropriate antidiuretic hormone Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differential Diagnosis
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Syndrome of inappropriate antidiuretic hormone classification On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Syndrome of inappropriate antidiuretic hormone classification All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Syndrome of inappropriate antidiuretic hormone classification
CDC on Syndrome of inappropriate antidiuretic hormone classification
Syndrome of inappropriate antidiuretic hormone classification in the news
Blogs on Syndrome of inappropriate antidiuretic hormone classification
Directions to Hospitals Treating Syndrome of inappropriate antidiuretic hormone
Risk calculators and risk factors for Syndrome of inappropriate antidiuretic hormone classification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vindhya BellamKonda, M.B.B.S [2]

Overview

SIADH may be classified into several sub-types based on the pattern of arginine vasopressin (AVP) secretion in response to a range of plasma osmolalities into type A, type B, type C, and type D.

Classification

SIADH may be classified into several sub-types based on the pattern of arginine vasopressin (AVP) secretion across a range of plasma osmolalities:

This classification scheme includes Fenske's observation on copeptin levels, which is "secreted in an equimolar amount to arginine vasopressin (AVP) but can easily be measured in plasma or serum with a sandwich immunoassay." Normal observations for copeptin are:

• Level during euvolemia: 2 and 38 pmol/L". Another view is "Median copeptin levels were significantly higher in the male volunteers compared with the females [median (range): 4.3 (0.4-44.3) compared with 3.2 (1.0-14.8) pmol/l" and levels are modulated by gender (higher in males), eGFR higher when eGFR lower), left atrial size (higher when LA larger), and longer echocardiographic deceleration times (prolonged ventricular filling).
• Slope of change during hypertonic saline infusion: "slope of 0.74 pmol/L and mOsM/kg H₂O ... (95% confidence interval [95% CI], 0.66 to 0.83)"

Classification	Features
Type A	Accounts for about 60-70% of SIADH Excessive secretion of arginine vasopressin (AVP) is noted "Plasma copeptin consistently >38 pmol/L with a copeptin slope <95% CI for that of healthy persons (i.e., <0.66 pmol/L/mOsM/kg H2O)" Associated with lung cancer and nasopharyngeal tumors Patients are more susceptible to development of severe hyponatremia
Type B	Accounts for (20–40%) of the cases "Any plasma copeptin concentration with a positive copeptin slope >0.25 pmol/L/mOsM/kg H2O, but a low osmotic threshold <95% CI for that of healthy persons (i.e., <281 mOsM/kg H2O)" Type B may include reset osmostat, "characterized by a decline in plasma copeptin levels with increasing saline-stimulated serum osmolality...baseline hypovolemia could not be identified...Theoretically, an alternative explanation of type E could be a reversed osmotic response from stimulation to inhibition" Secretion of AVP occurs at lower than normal plasma osmolalities
Type C	Failure to suppress AVP secretion at plasma osmolalities below the osmotic threshold "Plasma copeptin concentration between 2 and 38 pmol/L with a copeptin slope between −0.25 and 0.25 pmol/L/mOsM/kg H2O" Type C may include reset osmostat, "reset osmostat may in part be considered as a less severe variant of the type C defect..., where responsivity to osmotic challenges is completely lost. Copeptin release in this subtype was stable at levels within the normal physiologic range but was not suppressed by hypotonicity or stimulated in response to osmotic stimulation; thus, it deviates from the previously described type C" Occurs due to dysfunction of inhibitory neurons in the hypothalamus, leading to persistent low-grade basal AVP secretion
Type D	Low or undetectable AVP levels and circulating AVP response is not defective "Plasma copeptin concentration consistently <2 pmol/L regardless of the copeptin slope" Nephrogenic SIADH (NSIAD) may be attributed to this condition Associated with gain-of-function mutations in the vasopressin-2 (V2) receptor leading to a clinical picture of SIADH, with undetectable AVP levels The condition is inherited in an X-linked manner, although heterozygous females may have inappropriate anti-diuresis of varying degrees.
Type E	"Any plasma copeptin concentration with a copeptin slope <−0.25 pmol/L/mOsM/kg H2O"